# Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

> **NCT01059305** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Skin Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01059305
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Lack of primary outcome efficacy.
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059305, "Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01059305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*